Please check your internet connection and try again.
# Montelukast-Levocetirizine
## Overview
A fixed-dose combination (FDC) therapy typically used for allergic rhinitis. Montelukast is a selective, competitive leukotriene receptor antagonist. Levocetirizine is the R-enantiomer of cetirizine, a potent, non-sedating (though somnolence is noted) H1-receptor antagonist.
## Primary Indications
* Allergic rhinitis (seasonal and perennial).
* Chronic urticaria (off-label for combination utility).
* *Note: Montelukast monotherapy is indicated for asthma; the combo is generally reserved for allergic rhinitis.*
## Adult Dosing
* **Combination:** Standard FDC preparations contain **Montelukast 10 mg / Levocetirizine 5 mg**.
* **Frequency:** 1 tablet orally once daily, typically in the evening.
## Pediatric Dosing
* **Ages 6 to 14 years:** Montelukast 5 mg / Levocetirizine 2.5 mg once daily.
* **Ages < 6 years:** FDC is generally not recommended; individual components should be titrated separately based on weight and age-appropriate formulations.
## Dose Adjustments
* **Renal Impairment:** Levocetirizine requires renal dose adjustment. For CrCl < 50 mL/min, the levocetirizine component is typically reduced in frequency or dose.
* **Hepatic Impairment:** No specific adjustment for Montelukast, but monitor for hepatic side effects; Levocetirizine typically does not require adjustment here.
## Contraindications
* Hypersensitivity to montelukast, levocetirizine, cetirizine, or any component of the formulation.
* Severe renal impairment (CrCl < 10 mL/min) or patients undergoing hemodialysis (for levocetirizine component).
## Adverse Effects
* **Neuropsychiatric (Montelukast):** Agitation, aggression, depression, sleep disturbances, and suicidal thinking/behavior (Black Box Warning).
* **CNS (Levocetirizine):** Somnolence (common), fatigue, and nasopharyngitis.
* **Other:** Headache, dry mouth, and rare cases of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
## Key Drug Interactions
* **CYP2C8/2C9/3A4 Inhibitors (e.g., gemfibrozil):** May increase montelukast exposure.
* **CNS Depressants:** Concurrent use with alcohol, benzodiazepines, or opioids may increase sedation from levocetirizine.
* **Ritonavir:** May increase plasma concentrations of levocetirizine.
## Monitoring
* Monitor for changes in mood, behavior, or sleep patterns (Black Box Warning for Montelukast).
* Monitor renal function periodically in patients with baseline impairment.
* Monitor for signs of exacerbation of underlying asthma if the patient is using montelukast for concurrent respiratory symptoms.
## Clinical Pearls
* **Black Box Warning:** The FDA mandates a warning for montelukast regarding serious neuropsychiatric events. It should be reserved for use in allergic rhinitis only when other treatments are inadequate or inappropriate.
* **Timing:** Administer in the evening to optimize coverage for nocturnal symptoms and accommodate the sedative potential of levocetirizine.
* **Alternatives:** Consider if the patient truly requires both mechanisms; monotherapy with an intranasal corticosteroid is often first-line for allergic rhinitis.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and local formulary protocols vary. Always verify exact dosing, safety profiles, and current contraindications via the most recent manufacturer prescribing information and institutional pharmacy resources before prescribing or administering medication.
